Maximum amount of milestone payments payable under license agreement.

No definition available.

Name:	mnk_MilestonePaymentMaximumAmount
Namespace Prefix:	mnk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payment made in connection with a license agreement.

+ References

No definition available.

+ Details

Name:	mnk_MilestonePayments
Namespace Prefix:	mnk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payment made upon FDA approval in connection with a license agreement.

+ References

No definition available.

+ Details

Name:	mnk_MilestonePaymentsFDAApproval
Namespace Prefix:	mnk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of Nuclear Reactors Relied on For Supply of Raw Material

+ References

No definition available.

+ Details

Name:	mnk_NumberofNuclearReactorsReliedonForSupplyofRawMaterial
Namespace Prefix:	mnk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Nuclear Research Reactors Used To Source Raw Material

+ References

No definition available.

+ Details

Name:	mnk_NumberofNuclearResearchReactorsUsedToSourceRawMaterial
Namespace Prefix:	mnk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Suppliers of Unique Raw Material

+ References

No definition available.

+ Details

Name:	mnk_NumberofSuppliersofUniqueRawMaterial
Namespace Prefix:	mnk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Restricted Cash, Fair Value Disclosure

+ References

No definition available.

+ Details

Name:	mnk_RestrictedCashFairValueDisclosure
Namespace Prefix:	mnk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 35

-Paragraph 1

-Subparagraph b

-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 25

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 55

-Paragraph 37

-URI http://asc.fasb.org/extlink&oid=25498275&loc=d3e2207-128464

+ Details

Name:	us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Fair value portion of the amount that could be realized under a life insurance contract or contracts owned by the entity, commonly known as corporate-owned life insurance (COLI) or bank-owned life insurance (BOLI).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Surrender Value

-URI http://asc.fasb.org/extlink&oid=6507153

+ Details

Name:	us-gaap_CashSurrenderValueFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueInputsDiscountRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

Financial Instruments and Fair Value Measurement (Narrative) (Details)	12 Months Ended															12 Months Ended					12 Months Ended
	Sep. 26, 2014 supplier reactor	Sep. 26, 2014 CNS Therapeutics, Inc. USD ($)	Oct. 01, 2012 CNS Therapeutics, Inc. USD ($)	Sep. 26, 2014 Questcor Pharmaceuticals, Inc. USD ($)	Aug. 14, 2014 Questcor Pharmaceuticals, Inc. USD ($)	Sep. 26, 2014 Secured Debt 2.85% Term Loan Level 3	Sep. 26, 2014 Secured Debt 4.00% Term Loan Level 3	Sep. 26, 2014 Debentures 8.00% Debentures Level 2	Sep. 26, 2014 Debentures 9.50% Debentures Level 2	Apr. 30, 2013 Senior Notes 3.50% Notes	Sep. 26, 2014 Senior Notes 3.50% Notes Level 1	Apr. 30, 2013 Senior Notes 4.75% Notes	Sep. 26, 2014 Senior Notes 4.75% Notes Level 1	Aug. 13, 2014 Senior Notes 5.75% Notes	Sep. 26, 2014 Senior Notes 5.75% Notes Level 1	Sep. 26, 2014 Synacthen Questcor Pharmaceuticals, Inc. USD ($)	Sep. 26, 2014 Other assets Level 1 USD ($)	Sep. 27, 2013 Other assets Level 1 USD ($)	Sep. 26, 2014 Other assets Level 3 USD ($)	Sep. 27, 2013 Other assets Level 3 USD ($)	Sep. 26, 2014 BioVectra, Inc. Questcor Pharmaceuticals, Inc. CAD	Sep. 26, 2014 Fiscal 2015 and 2016 Synacthen Questcor Pharmaceuticals, Inc. USD ($)	Sep. 26, 2014 Fiscal 2015 and 2016 Prepaid expenses and other current assets Synacthen Questcor Pharmaceuticals, Inc. USD ($)	Sep. 26, 2014 Subsequent to Fiscal 2016 Synacthen Questcor Pharmaceuticals, Inc. USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration upon acquisition			$ 6,900,000		$ 0
Maximum contingent payments for acquisition			9,000,000
Discount rate		1.00%														4.70%					1.30%
Fair value of contingent liability		7,000,000		195,800,000	195,400,000																45,000,000
Milestone payments																						25,000,000	25,000,000	25,000,000
Milestone payment, upon FDA approval																25,000,000
Milestone payment, maximum amount																215,000,000
Restricted cash																	69,800,000	24,000,000
Cash surrender value of life insurance																			$ 69,000,000	$ 67,700,000
Stated interest rate						2.85%	4.00%	8.00%	9.50%	3.50%	3.50%	4.75%	4.75%	5.75%	5.75%
Number of Mo-99 suppliers	8
Number of nuclear research reactors supplying Mo-99	3
Number of nuclear research reactors relied upon for Mo-99 supply	2